📊 TIL Key Takeaways
Is Instil Bio, Inc. (TIL) a Good Investment?
Instil Bio exhibits critical fundamental weakness with zero revenue (100% YoY decline) and negative operating cash flow (-$1.3M) against only $5.0M in available cash, implying 3-4 quarters of runway. Despite a strong balance sheet with $110.7M equity and zero debt, the absence of commercialized products and accelerating cash burn poses existential risk to the clinical-stage biotech.
Instil Bio, Inc. Key Strengths (TIL)
- Strong balance sheet with $200.4M total assets and $110.7M stockholders equity
- No long-term debt; debt-to-equity ratio of 0.00x
- Improving net loss (-$4.2M) and EPS (-$0.62) trending positively YoY
TIL Stock Risks: Instil Bio, Inc. Investment Risks
- Zero revenue with 100% YoY decline; no apparent commercialized products
- Negative operating cash flow (-$1.3M) with critically low cash reserves ($5.0M)
- Insufficient cash runway (~3-4 quarters) to fund operations without capital raise or strategic event
- No insider buying activity in 90-day period suggests management confidence deficit
Key Metrics to Watch
- Cash position and burn rate; timeline to next financing event
- Clinical trial progress and regulatory pathway status
- Operating cash flow trend and path to revenue generation
Instil Bio, Inc. (TIL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 39.87x current ratio provides a solid financial cushion.
TIL Profit Margin, ROE & Profitability Analysis
TIL vs Healthcare Sector: How Instil Bio, Inc. Compares
How Instil Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Instil Bio, Inc. Stock Overvalued? TIL Valuation Analysis 2026
Based on fundamental analysis, Instil Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Instil Bio, Inc. Balance Sheet: TIL Debt, Cash & Liquidity
TIL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Instil Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-11.39 indicates the company is currently unprofitable.
TIL Revenue Growth, EPS Growth & YoY Performance
TIL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | N/A | -$4.1M | $-0.33 |
| Q2 2021 | N/A | -$4.1M | $-0.27 |
| Q1 2021 | N/A | -$4.1M | $-0.31 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Instil Bio, Inc. Dividends, Buybacks & Capital Allocation
TIL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Instil Bio, Inc. (CIK: 0001789769)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TIL
What is the AI rating for TIL?
Instil Bio, Inc. (TIL) has an AI grade of D with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TIL's key strengths?
Claude: Strong balance sheet with $200.4M total assets and $110.7M stockholders equity. No long-term debt; debt-to-equity ratio of 0.00x.
What are the risks of investing in TIL?
Claude: Zero revenue with 100% YoY decline; no apparent commercialized products. Negative operating cash flow (-$1.3M) with critically low cash reserves ($5.0M).
What is TIL's revenue and growth?
Instil Bio, Inc. reported revenue of $0.0.
Does TIL pay dividends?
Instil Bio, Inc. does not currently pay dividends.
Where can I find TIL SEC filings?
Official SEC filings for Instil Bio, Inc. (CIK: 0001789769) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TIL's EPS?
Instil Bio, Inc. has a diluted EPS of $-0.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TIL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Instil Bio, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TIL stock overvalued or undervalued?
Valuation metrics for TIL: ROE of -3.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TIL's AI grade for 2026?
Our dual AI analysis gives Instil Bio, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TIL's free cash flow?
Instil Bio, Inc.'s operating cash flow is $-1.3M, with capital expenditures of $0.0.
How does TIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -3.8% (avg: 15%), current ratio 39.87 (avg: 2).